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p53, sometimes referred to as the ‘‘guardian of the genome,’’ helps regulate cell-cycle arrest, DNA-damage
repair, apoptosis, and senescence. Adding to this list, in this issue ofCell StemCell, Liu et al. (2009) show that
p53 also plays a role in regulating hematopoietic stem cell quiescence.The tumor suppressor p53 is a key tran-
scription factor that functions at the
convergence of several signaling path-
ways involved in the cellular stress
response. Upon stress-induced activa-
tion, p53 accumulates and mediates the
expression of target genes designed to
protect the genetic integrity of the cell.
These protection mechanisms include
the arrest of cell-cycle progression at the
G1/S checkpoint (mediated by p21),
activation of DNA repair machinery,
induction of apoptotic cell death, or initia-
tion of senescence or differentiation
programs.
Now, it appears that p53 has yet
another important function
that is independent of its role
as a regulator of the stress
response. In this issue of
Cell Stem Cell, Liu and
colleagues (2009) show that
p53 is essential for maintain-
ing hematopoietic stem cell
(HSC) quiescence during
steady-state hematopoiesis.
Hematopoiesis is critically
dependent on the ability of
at least a subset of HSCs to
maintain a quiescent state,
which confers resistance to
radiation, cytotoxic insults,
and oxidative stress and
ensures that the population
is sufficiently long-lived to
maintain lifelong blood cell
production. While several
transcription factors have
already been identified as
regulators of HSC quies-
cence, including HoxB4,
STAT5, Gfi-1, SMAD4, c-myc,
and Mef (reviewed in Zon,
2008), p53 was not known to be involved.
Liu and colleagues (2009) show that p53-
deficient mice have an increased HSC
pool size, consistent with a previous report
(TeKippe et al., 2003), but a decreased
proportion of that pool exhibits quies-
cence. In addition, the authors demon-
strate that p53 mediates HSC quiescence
independently of p21, and they identified
Gfi-1 and Necdin as alternate, direct
targets of p53 in this context. Gfi-1 has
been previously reported to mediate HSC
quiescence (Hock et al., 2004), and
although Necdin has been shown to be
a negative cell-cycle regulator in post-
mitotic neurons (Yoshikawa, 2000), it has
not been previously associated with HSC
homeostasis.
In an earlier study, also reported by the
Nimer group, Mef deficiency was shown
to lead to increased HSC quiescence
and enhanced self-renewal and conferred
a competitive advantage uponHSC trans-
plantation (Lacorazza et al., 2006). In the
current report, the authors demonstrate
that the HSC quiescence phenotype
induced by Mef deficiency requires p53
but that the enhanced self-renewal
phenotype and competitive transplant
advantage exhibited by Mef knockout
cells are p53 independent. Collectively,
the results suggest that the role of p53 in
HSC quiescence is indepen-
dent of its classical role con-
ducted in response to cellular
stress (Figure 1).
Quiescence and self-
renewal are two of the most
essential characteristics of
HSCs. Therefore, it is some-
what puzzling why Mef-defi-
cient HSCs exhibit increased
self-renewal in combination
with an elevated proportion of
quiescent cells, while p53-
deficient mice display in-
creased self-renewal and low
levels of quiescence. Further,
without the ability to assay
HSC function after serial trans-
plantation, it remains possible
that increased self-renewal as
reported by Liu et al. and La-
corazzaetal. ismerelya reflec-
tion of an increase in the
number of stem cells and not
an increased repopulation
potential per (individual) stem
cell. Therefore, the expansion
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Figure 1. Independent Roles of p53 in the Cellular Stress Response,
HSC Quiescence, and HSC Self-Renewal
(A) The cellular stress response of p53 is mediated by p21 and can lead to cell-
cycle arrest, DNA-damage repair, cellular senescence, or apoptosis.
(B) Although quiescence and self-renewal are related processes, the data
presented by Liu et al. suggest that they are (at least partly) independently
regulated by Mef and p53. It should be noted that increased self-renewal
was measured as an increase in the number of (transplantable) stem cells
and not as an increased number of stem cells generated by division of a single
stem cell. Concerning quiescence,Mef acts to inhibit the action of p53 onGfi-1
and necdin, which normally help maintain quiescence.
(C) Concerning self-renewal or the size of the stem cell pool, Mef and p53 exert
independent functions through unknown intermediates.Cell Stem Cell 4, January 9, 2009 ª2009 Elsevier Inc. 7
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Previewsof HSCs observed in p53-deficient mice,
taken in context of the corresponding
decrease in the quiescent fraction, could
indicate that HSC function would be ex-
hausted after multiple rounds of stress-
induced expansion. Unfortunately, the
tumorigenicity ofp53-deficient cellsmakes
this a difficult, if not impossible, hypothesis
to test. Nonetheless, the varied pheno-
types observed between the single- and
double-mutant HSCs suggest that both
Mef and p53 are involved in regulating
HSC expansion as well as quiescence,
but whether or not downstream targets
Gfi-1, Necdin, or p21 are involved in the
regulation of self-renewal remains unclear.
Downmodulation of Necdin diminished
the quiescence-inducing effect in Mef null
mice,butdataonself-renewalarenotavail-
able. These results combinedwith thepref-
erential expression of Necdin by primitive
stemcells also identifyNecdinas an impor-
tant protein in hematopoietic stem cell
regulation.
Themechanism by whichMef regulates
p53 is unclear. Possibilities include a
direct effect on p53 expression levels, an
alteration of p53 stability or activation
state, or even effects on p53 coregulators
such as Mdm2. Since the authors have
found that p53 is upregulated inMef-defi-
cient fibroblasts, the first option seems
plausible, but the authors did not report on
the relative p53 expression levels in Mef-
deficient HSCs, so this question remains
unresolved. Liu et al. also show convinc-
ingly that the level of quiescence deter-
mines HSC radiation sensitivity and that
the increased radiation resistance ob-
served inMef-deficient HSC is not depen-
dent on p53/p21. Curiously, the sensitivity
of double-knockout HSC to radiation
seems to be even higher than expected
from the single knockouts (see Figures
4C and 4D in the paper). This result would
not be predicted by the simple model
described in Figure 1 and suggests that
additional mechanisms may be involved.
The relationship between reversible
stem cell quiescence and irreversible
stem cell senescence, and how this
balance changes during aging, is an area8 Cell Stem Cell 4, January 9, 2009 ª2009 Eof intense interest. Constitutive expres-
sion of p53 has been associated with
premature aging (Tyner et al., 2002). Since
p53 is a downstream target ofMef, it is ex-
pected to be continuously activated in
Mef null mice. Therefore, onemay wonder
how HSC aging might be affected in the
case of Mef deficiency, in either the
absence or presence of p53. It seems
possible that the large pool of quiescent
stem cells that accumulates in the
absence of Mef could overcome the
decline in HSC function observed during
the aging process. However, the larger
pool of HSCs combined with their higher
self-renewal capacity might also provide
fertile ground for the development of
leukemia. This hypothesis is supported
by the observation that Mef is expressed
in a significant proportion of ovarian carci-
nomas, and in ovarian cancer cell lines,
but not in normal ovarian surface epithe-
lium. (Yao et al., 2007). Therefore, Mef
might be classified as a (proto)oncogene.
A molecular balance between self-
renewal and proliferation may prevent
cancer, but signaling pathways that regu-
late normal stem-cell self-renewal may
cause neoplastic proliferation when not
properly regulated (reviewed by Pardal
et al., 2003). During aging, maintenance
of HSC quiescence may be impaired by
unfaithful replication of epigenetic marks,
resulting in aberrant gene expression.
Genes involved in regulation of such
epigenetic marks, including BMI-1, Ezh2,
Mel-18, Suz12, and Rae28, have all been
shown to affect stem cell maintenance
and self-renewal (reviewed in Zon, 2008).
Aberrant gene expression of these and
other genes may directly lead to transfor-
mation or may indirectly induce low levels
of cellular damage, which in turn may up-
regulate genes such as p16 but also p53.
Unfortunately, a role of p53 in stem cell
aging is likely to remain obscured by
its well-known function as a tumor
suppressor gene.
Finally, with the discovery of p53 as yet
another protein involved in HSC mainte-
nance, the commonly used statement
that the mechanisms involved in stemlsevier Inc.cell regulation remain unknown no longer
seems appropriate or fully accurate. In
reality, the list of genes involved in HSC
regulation is ever expanding, and each
new discovery contributes to a growing
appreciation for the complexity of the
system. Some of these candidate genes
seem to affect self-renewal and others
quiescence, two related and vital charac-
teristics of HSC. Interestingly, Mef is not
a stereotypical stem cell gene, as it is
expressed at very low levels in HSCs.
However, the low expression of Mef in
HSCs compared to more differentiated
cell types is in line with its proposed role
as an inhibitor of p53-induced quiescence
during steady-state hematopoiesis (Fig-
ure 1). The paper by Liu and colleagues
identifies p53 as an important player in
the maze of genes involved in regulation
of HSC self-renewal and quiescence.
Undoubtedly, more genes will be identi-
fied, and further research should be
directed to investigate molecular interac-
tions between the different gene products
to uncover the full regulatory network
involved in HSC regulation.
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